Akoustis Technologies Inc Stock
Currently there is a rather positive sentiment for Akoustis Technologies Inc with 3 Buy predictions and 0 Sell predictions.
With a target price of 28 € there is potential for a 5599900.0% increase which would mean more than doubling the current price of 0.0 € for Akoustis Technologies Inc.
Our community identified positive and negative aspects for Akoustis Technologies Inc stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Akoustis Technologies Inc stock. On the other hand our users think that "Credit Rating" could be a problem in the future.
Pros and Cons of Akoustis Technologies Inc in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akoustis Technologies Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akoustis Technologies Inc | - | - | - | - | - | - | - |
| Asure Software | 0.000% | 9.333% | 7.895% | -0.606% | 3.797% | -29.310% | 16.312% |
| Overstock.com | -6.450% | 8.560% | 33.493% | 4.104% | 20.077% | -69.657% | -92.706% |
| Egain Communications | 0.000% | 10.000% | 3.937% | 42.857% | -22.807% | -0.752% | -20.482% |
Comments
Aktis Oncology (AKTS) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for AKTS provided by MarketBeat
Aktis Oncology (AKTS) is now covered by William Blair. They set an "outperform" rating on the stock.
Show more
Ratings data for AKTS provided by MarketBeat
Aktis Oncology (AKTS) had its price target raised by HC Wainwright from $30.00 to $33.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKTS provided by MarketBeat